AbbVie sweeps out experimental gastro drugs in a post-merger pipeline cleanup. And they can likely be yours for the right price
AbbVie never wanted all the pipeline projects on display at Allergan. And now the pharma giant is writing off an $80 million investment in a microbiome deal as part of its post-merger R&D revamp.
Allergan initially plunked down $50 million to get the collaboration on their microbiome gastrointestinal programs started with Assembly Biosciences $ASMB, Mizuho’s Salim Syed estimated that their total spend was around $80 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.